are in the stages of preclinical development. 3 Spf 66, a multi-component synthetic peptide with amino acid sequences derived from three P. falciparum asexual erythrocytic stage proteins. This vaccine has undergone extensive trial and was found to be safe and immunogenic. 21, 22 In Tanzania, it showed protective efficacy in 31% in children aged 1-5 years. 23 However, results from a study in the Gambia failed to demonstrate protection against Malaria in infants of 6-11 months of age. 24 The results from a recent study in children of 2-15 years old in Thailand indicated no protection. 25 One further trial, among infants in Tanzania is in progress. 20 Inspite of mixed results, the field trials conducted till now with Spf 66 have had an impact on thinking and the
